Genesis Biopharma terminates previously announced proposed public offering

Download PDF Copy

May 8 2012

NewsGuard 100/100 Score

Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announced today that it is terminating its previously announced proposed public offering pursuant to a preliminary prospectus supplement and an effective shelf registration statement on file with the Securities and Exchange Commission due to market conditions.

"The Company intends to pursue alternative financing under more favorable conditions", stated Anthony Cataldo, President & Chief Executive Officer of Genesis Biopharma, Inc.

Source:

Genesis Biopharma, Inc.

Posted in: Business / Finance

Tags: Biotechnology, Cancer, Cell, Immunotherapy, Melanoma

Comments (0)

Download PDF Copy

Suggested Reading

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths

Air pollution linked to head and neck cancer risk

Air pollution linked to head and neck cancer risk

How different types of bread impact cancer risk

How different types of bread impact cancer risk

Innovative urine test could improve pancreatic cancer survival rates

Innovative urine test could improve pancreatic cancer survival rates

Researchers uncover key genes linked to DCIS progression

Researchers uncover key genes linked to DCIS progression

Study shows cannabis as a genotoxic substance with cancer risks

Study shows cannabis as a genotoxic substance with cancer risks

Study shows AI can predict prognosis in triple-negative breast cancer

Study shows AI can predict prognosis in triple-negative breast cancer

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

AI-powered tool predicts gene activity in cancer cells from biopsy images